<i>S</i>. Typhimurium infection results in energy loss and transient activation of AMPK.

<p><b>(A)</b> ATP levels in BMDMs upon <i>S</i>. Typhimurium was analyzed by mass spectrometry and the mass peak intensity is depicted in the graph as mean ± SEM, ***p≤0.001 (n = 6). <b>(B)</b> Intracellular NAD⁺ and NADH levels form uninfected and <i>S</i>. Typhimurium-infected BMDMs were measured using NAD+/NADH assay kit. Bar graphs are expressed as mean ± SEM, ***p≤0.001 (n = 3). <b>(C)</b> Immunoblot analysis of AMPK, ACC and LKB1 expression upon <i>S</i>. Typhimurium infection in BMDMs cells. <b>(D)</b> Mean densitometric analysis of immunoblots is shown. Data are representative of 3 independent experiments. Bar graphs are expressed as mean ± SEM, ***p≤0.001 and **p≤0.01. <b>(E)</b> Confocal image showing AMPK-LKB1 (n = 4). (<b>F</b>) Pearson’s correlation coefficient of AMPK with LKB1 analyzed from 50 regions of interest (ROI). <b>(G)</b> AMPK-LysoTracker Red co-localization (n = 4). <b>(H)</b> Pearson’s correlation coefficient of AMPK with LysoTracker Red analyzed from 50 ROIs. <b>(I)</b> LKB1-LysoTracker Red co-localization in BMDMs upon <i>S</i>. Typhimurium infection n = 3. (<b>J</b>) Pearson’s correlation coefficient of LKB1-LAMP1 co-localization calculated by measuring minimum of 50 ROI using olympus fluoview fv1000 software. Scale bar = 10μm for microscopy images. <b>(K)</b> Total AMPK and LKB1 expression upon <i>S</i>. Typhimurium infection in BMDMs treated with concanamycinA (concA) or MG132. Western blots are representative of three experiments. <b>(L)</b> Mean densitometric data of protein expression were analyzed using NIH Image J software. Bar graphs are expressed as mean ± SEM, ns non-significant, ***p≤0.001 and **p≤0.01.</p

<i>S</i>. Typhimurium triggered cytosolic translocation and degradation of Sirt1 involves AKT.

<p><b>(A)</b> Immunoblot analysis of AKT activation upon <i>S</i>. Typhimurium infection in BMDMs. <b>(B)</b> The phosphorylated and total AKT amounts are quantified by densitometric analysis. Data shown are representative of at least 3 independent experiments. Bar graphs are expressed as mean ± SEM, ***p≤0.001, **p≤0.01 and *p≤0.05. <b>(C)</b> Protein expression of AKT, Sirt1, GAPDH and ACC from BMDMs pretreated with or without AKT inhibitor VIII prior to infection with <i>S</i>. Typhimurium. Western bots are representative of 3 independent experiments. <b>(D)</b> The phosphorylated AKT, ACC and Sirt1 amounts are quantified by densitometric analysis. Bar graphs are expressed as mean ± SEM, ***p≤0.001, **p≤0.01 and *p≤0.05. (<b>E</b>) Confocal immunofluorescence image showing Sirt1-LysoTracker Red co-localization in BMDMs pretreated with AKT inhibitor VIII followed by <i>S</i>. Typhimurium infection. BMDMs untreated with AKT inhibitor VIII but infected with <i>S</i>. Typhimurium for 4h is shown for comparison (n = 3). <b>(F)</b> Pearson’s correlation coefficient of Sirt1 with LysoTracker Red calculated by measuring 35 ROIs. <b>(G)</b> Sirt1- <i>S</i>. Typhimurium co-localization in BMDMs pretreated with AKT inhibitor VIII followed by <i>S</i>. Typhimurium infection (n = 3). Scale bar = 10μm for microscopical images. <b>(H)</b> Quantitation of LysoTracker Red co-localization with SCVs. 100 SCVs were counted and expressed as percentage co-localization. Bar graphs are expressed as mean ± SEM, ***p≤0.001.</p

<i>S</i>. Typhimurium mediated targeting of Sirt1 for lysosomal degradation is virulence dependent.

<p>Immunoblot analysis of ACC and LKB1 activation upon infection with <i>ΔssrB</i> <b>(A)</b> and <i>ΔssaV</i> <b>(B)</b> compared to <i>S</i>. Typhimurium. Sirt1 and acetylated-NFκB from macrophages infected with <i>ΔssrB</i> <b>(C)</b> <i>and ΔssaV</i> <b>(D)</b> compared to <i>S</i>. Typhimurium. <b>(E)</b> Expression of Sirt1 from cytoplasmic (C) and nuclear (N) fraction from BMDMs infected with <i>ΔssrB</i>. <b>(F)</b> Confocal image of Sirt1 and LysoTracker Red in <i>ΔssrB</i>-infected BMDMs. Sirt1-LysoTracker Red co-localization in untreated BMDMs infected with <i>S</i>. Typhimurium for 4h is shown for comparison (n = 3). <b>(G)</b> Immunoblot analysis of LC3 and p62. <b>(H)</b> Densitometric analysis of LC3 lipidation and p62 (n = 4). <b>(I)</b> Immunofluorescence image of <i>ΔssrB</i>-infected BMDMs stained for LC3 and LPS of <i>S</i>. Typhimurium (n = 3). <b>(J)</b> Quantitation of LC3 co-localization with SCVs. 100 SCVs were counted and expressed as percentage co-localization. <b>(K)</b> AKT, mTOR, p70S6K, NDRG1 expression upon S. Typhimurium (ST) and <i>ΔssrB</i> infection in BMDMs. <b>(L)</b> Densitometric analysis of AKT, mTOR, p70S6K and NDRG1 are shown from 3 independent experiments. Bar graphs are expressed as mean ± SEM, ***p≤0.001. Scale bar = 10μm for microscopical images.</p

Increased mTOR activation leads to degradation of Sirt1 upon <i>S</i>. Typhimurium infection.

<p>(<b>A</b>) Immunoblot analysis of <i>S</i>. Typhimurium-infected BMDMs for mTOR and its downstream targets p70S6K and NDRG1. <b>(B)</b> Densitomertic analysis of phosphorylation amounts of mTOR, p70s6K and NDRG1. Data shown are representative of at least 3 independent experiments. Bar graphs are expressed as mean ± SEM, ***p≤0.001, **p≤0.01 and *p≤0.05. <b>(C)</b> Confocal image of Sirt1- <i>S</i>. Typhimurium. <b>(D)</b> Quantitation of LysoTracker Red co-localization with SCVs. 100 SCVs were counted and expressed as percentage co-localization. Bar graphs are expressed as mean ± SEM, ***p≤0.001. <b>(E)</b> Sirt1-LysoTracker Red co-localization in BMDMs pretreated with Torin1 followed by <i>S</i>. Typhimurium infection. Sirt1-LysoTracker Red co-localization in untreated-BMDMs infected with <i>S</i>. Typhimurium for 4h is shown for comparison (n = 3). <b>(F)</b> Pearson’s correlation coefficient of Sirt1 with LysoTracker Red calculated by measuring 35 selected regions of interest (ROI) using olympus fluoview fv1000 software. <b>(G)</b> Immunoblot analysis of Sirt1, ACC phosphorylation and S6Kinase activation in <i>S</i>. Typhimurium-infected BMDMs pretreated with Torin1. <b>(H)</b> Mean densitometric data of Sirt1 and phosphorylated ACC were analyzed and normalized to GAPDH and total ACC respectively (n = 3). Bar graphs are expressed as mean ± SEM, ***p≤0.001 and **p≤0.01. <b>(I)</b> Immunoblot of phosphorylated ACC in BMDMs transfected with control or Sirt1-expressing plasmids. Western blots are representative of three experiments. <b>(J)</b> Densitomertic analysis of phosphorylation amounts of ACC is shown from 3 independent experiments. Bar graphs are expressed as mean ± SEM, ***p≤0.001, **p≤0.01 and *p≤0.05.</p

<i>S</i>. Typhimurium evades autophagy by disrupting Sirt1-dependent AMPK activation.

<p><b>(A)</b> Immunofluorescence image of <i>S</i>. Typhimurium co-localization with LC3 in GFP-LC3 expressing BMDMs at indicated time points. Data shown are representative of 3 independent experiments (n = 3). <b>(B)</b> Immunoblot analysis of p62 and LC3 expression upon <i>S</i>. Typhimurium infection in BMDMs. <b>(C)</b> LC3 and p62 expression levels are quantified by densitometry analysis. Data shown are from 3 independent experiments. <b>(D)</b> Confocal image of macrophages stained for Sirt1 and LC3. <b>(E)</b> BMDMs stained for LC3 and AMPK upon <i>S</i>. Typhimurium infection. <b>(F)</b> Confocal image of macrophages stained for LKB1 and LC3. <b>(G)</b> Immunoblot analysis of Sirt1, AMPK and LKB1 in wild type (WT) and Atg7-deficient macrophages. <b>(H)</b> Densitometric analysis of Sirt1, AMPK and LKB1 immunoblots (n = 3). Bar graphs are expressed as mean ± SEM, ***p≤0.001, **p≤0.01 and *p≤0.05. Scale bar = 10μm for microscopical images.</p

Sirt1 is degraded upon <i>S</i>. Typhimurium infection.

<p><b>(A)</b> Confocal image of Sirt1 and LKB1 in BMDMs upon <i>S</i>. Typhimurium infection (n = 3). <b>(B)</b> Pearson’s correlation coefficient of Sirt1 with LKB1 calculated by measuring 42 ROIs. <b>(C)</b> Sirt1 was immunoprecipitated (IP) from uninfected and <i>S</i>. Typhimurium-infected BMDMs and the precipitated samples were immunoblotted (IB) for LKB1, AMPK and Sirt1 (n = 2). (<b>D</b>) Immunoblot of Sirt1, acetylated NFκB and GAPDH in BMDMs upon <i>S</i>. Typhimurium infection. Data shown are representative of 6 independent experiments. (<b>E</b>) Densitometric analysis of immunoblots. Bar graphs are expressed as mean ± SEM, ***p≤0.001 and **p≤0.01. (<b>F</b>) Immunofluorescence image of BMDMs stained for Sirt1 and <i>S</i>. Typhimurium (n = 4). <b>(G)</b> Quantitation of Sirt1-ST co-localization with SCVs. 100 SCVs were counted and expressed as percentage co-localization. Bar graphs are expressed as mean ± SEM, ***p≤0.001. (<b>H</b>) Sirt1-Lysotracker red co-localization in BMDMs upon <i>S</i>. Typhimurium infection (n = 4). <b>(I)</b> Pearson’s correlation coefficient of Sirt1 with Lysotracker red calculated by measuring minimum of 50 ROI. (<b>J</b>) Sirt1 expression upon <i>S</i>. Typhimurium infection in BMDMs treated with bafilomycinA (BafA), E64D, pepstatin A and calpeptin. <b>(K)</b> Sirt1 expression levels are quantified by densitometric analysis. Data shown are representative of 3 independent experiments. Bar graphs are expressed as mean ± SEM, ***p≤0.001 and **p≤0.01. <b>(L)</b> Sirt1 expression in nuclear (N) and cytoplasmic (C) fractions of BMDMs infected with <i>S</i>. Typhimurium. LaminB and GAPDH were used as housekeeping controls for nuclear and cytoplasmic fractions respectively (n = 2). Scale bar = 10μm for microscopical images.</p

A consortium of <i>Hordeum vulgare</i> and gut microbiota against non-alcoholic fatty liver disease via data-driven analysis

Despite many recent studies on non-alcoholic fatty liver disease (NAFLD) therapeutics, the optimal treatment has yet to be determined. In this unfinished project, we combined secondary metabolites (SMs) from the gut microbiota (GM) and Hordeum vulgare (HV) to investigate their combinatorial effects via network pharmacology (NP). Additionally, we analyzed GM or barley – signalling pathways – targets – metabolites (GBSTMs) in combinatorial perspectives (HV, and GM). A total of 31 key targets were analysed via a protein-protein interaction (PPI) network, and JUN was identified as the uppermost target in NAFLD. On a bubble plot, we revealed that apelin signalling pathway, which had the lowest enrichment factor antagonize NAFLD. Holistically, we scrutinized GBSTM to identify key components (GM, signalling pathways, targets, and metabolites) associated with the Apelin signalling pathway. Consequently, we found that the primary GMs (Eubacterium limosum, Eggerthella sp. SDG-2, Alistipes indistinctus YIT 12060, Odoribacter laneus YIT 12061, Paraprevotella clara YIT 11840, Paraprevotella xylaniphila YIT 11841) to ameliorate NAFLD. The molecular docking test (MDT) suggested that tryptanthrin-JUN is an agonist, conversely, dihydroglycitein-HDAC5, 1,3-diphenylpropan-2-ol-NOS1, and (10[(Acetyloxy)methyl]-9-anthryl)methyl acetate-NOS2, which are antagonistic conformers in the apelin signalling pathway. Overall, these results suggest that combination therapy could be an effective strategy for treating NAFLD.</p